Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...

Hamlet Gasoyan, MD, discussed the implications of a multiple myeloma study’s findings and their potential impact on clinical ...

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Arcellx Inc, a biotechnology firm focused on cell therapy innovations, has announced impressive results from its studies on ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

The applications are supported by data from the ongoing phase 3 AQUILA study (NCT03301220) of Darzalex Faspro as monotherapy for the treatment of adult patients with high-risk smoldering multiple ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

The following is a summary of “Evolving treatment landscape of multiple myeloma in Portugal: A nation-wide retrospective ...